A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma
Latest Information Update: 12 Oct 2020
At a glance
- Drugs Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 09 Oct 2020 This trial is completed in UK (Global End Date: 10 Jun 2013), according to European Clinical Trials Database record.
- 11 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 11 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.